dipipanone

09/01/1985 - "Mean pain cores on a computerised visual analogue scale were significantly higher after placebo than those after 4 mg (P less than 0.05) and 8 mg (P less than 0.01) dipipanone and a dose-response relationship was evident. "
03/01/1957 - "Dipipanone hydrochloride raised the threshold to ischaemic pain in healthy human volunteers. "
11/10/1956 - "Dipipanone hydrochloride in the treatment of severe pain; a report of 200 cases."
07/01/1987 - "Effects of triprolidine and dipipanone in the cold induced pain test, and the central nervous system of healthy volunteers."
12/01/1987 - "Dipipanone and nifedipine in cold induced pain; analgesia not due to skin warming."

01/01/1990 - "In contrast to dipipanone, 443C81 did not cause significant miosis or reduce minute volume on rebreathing CO2 and there was no evidence of sedation. "
01/01/1985 - "In the first study IV naloxone significantly inhibited analgesia, miosis and sedation produced by the opioid dipipanone 10 mg in 12 subjects. "

05/14/2015 - "We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group Specialized Register, on 13 June 2014 using the terms: narcotic OR opioid OR opium OR morphine OR buprenorphine OR codeine OR dextromoramide OR diphenoxylate OR dipipanone OR dextropropoxyphene OR propoxyphene OR diamorphine OR dihydrocodeine OR alfentanil OR fentanyl OR remifentanil OR meptazinol OR methadone OR nalbuphine OR oxycodone OR papaveretum OR pentazocine OR meperidine OR pethidine OR phenazocine OR hydrocodone OR hydromorphone OR levorphanol OR oxymorphone OR butorphanol OR dezocine OR sufentanil OR ketobemidone.ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases such as MEDLINE, EMBASE and PscyINFO, as well as numerous trial registries and grey literature sources. "

01/01/1994 - "Experience with dipipanone elixir in the management of cancer related pain--case study."
01/01/1994 - "We present three patients in which dipipanone elixir proved to be their own drug of choice in the management of opioid responsive cancer pain, and our experience with 15 other patients. "